2 results
Approved WMOWill not start
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Approved WMOWill not start
Collect clinical data in order to confirm the clinical safety and performance of the Pamira lead when used in routine clinical practice to support the regulatory post-market strategy in Europe and other regions and validation of promotional claims…